Angle PLC (LSE: AGL) is a UK-based liquid biopsy company developing Parsortix®, a platform for capturing circulating tumour cells (CTCs) in blood. Its technology enables early cancer detection and personalised treatment. With applications across oncology diagnostics and research, Angle supports the shift toward non-invasive precision medicine.